Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ranitidine
Accession Number
DB00863  (APRD00254)
Type
Small Molecule
Groups
Approved
Description

Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist. This drug helps to prevent and treat gastric-acid related conditions, including ulcers, because of its ability to decrease gastric acid secretion 2, Label. It is often referred to as Zantac, and is available in various forms, including a regular tablet, injection, and effervescent tablet Label, 9.

One common use of this drug is to relieve the symptoms of gastric esophageal reflux disease (GERD) Label, which often leads to heartburn symptoms and acid regurgitation. The prevalence of GERD is thought to be 10-20% in western countries 4. Ranitidine has proven to be an effective agent in relieving the above symptoms and is therefore widely used in GERD and other gastric-acid related conditions 5, Label.

Structure
Thumb
Synonyms
  • Ranitidina
  • Ranitidine
  • Ranitidinum
Product Ingredients
IngredientUNIICASInChI Key
Ranitidine bismuth citrate7AJ51I17KG128345-62-0XAUTYMZTJWXZHZ-UHFFFAOYSA-K
Ranitidine hydrochlorideBK76465IHM66357-59-3GGWBHVILAJZWKJ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid ReducerTablet150 mgOralPendopharm Division Of Pharmascience IncNot applicableNot applicableCanada
Act RanitidineTabletOralTEVA Canada Limited2004-04-19Not applicableCanada
Act RanitidineTabletOralTEVA Canada Limited2004-02-19Not applicableCanada
Bci RanitidineTabletOralBaker Cummins IncNot applicableNot applicableCanada
Bci RanitidineTabletOralBaker Cummins IncNot applicableNot applicableCanada
DeprizineKit6.4 g/6.4gOralCalifornia Pharmaceuticals, Llc2016-01-012018-01-05Us
DeprizineKit4.2 g/4.2gOralFusion Pharmaceuticals LLC2010-02-082014-08-01Us
M-ranitidineTabletOralMantra Pharma Inc2018-12-11Not applicableCanada
M-ranitidineTabletOralMantra Pharma Inc2018-12-11Not applicableCanada
PyloridTabletOralGlaxo Wellcome1997-08-292000-07-27Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ag-ranitidineTabletOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-ranitidineTabletOralAngita Pharma Inc.2019-08-14Not applicableCanada
Apo-ranitidineSolutionOralApotex Corporation2006-07-14Not applicableCanada
Apo-ranitidine Tablet 150mgTabletOralApotex Corporation1987-12-31Not applicableCanada
Apo-ranitidine Tablet 300mgTabletOralApotex Corporation1987-12-31Not applicableCanada
Dom-ranitidineTabletOralDominion Pharmacal2001-03-22Not applicableCanada
Dom-ranitidineTabletOralDominion Pharmacal2001-03-22Not applicableCanada
Good Sense Acid ReducerTablet75 mg/1Oralbryant ranch prepack2009-05-21Not applicableUs
Jamp-ranitidineTabletOralJamp Pharma Corporation2018-10-24Not applicableCanada
Jamp-ranitidineTabletOralJamp Pharma Corporation2018-10-24Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select Acid ReducerTablet, film coated150 mg/1Oral7-Eleven2014-04-222020-11-30Us
Acid ReducerTablet150 mg/1OralSelect Brand2012-03-30Not applicableUs
Acid ReducerTabletOralVita Health Products Inc2008-01-31Not applicableCanada
Acid ReducerTablet75 mg/1OralShopko Stores Operating2013-06-102014-12-02Us
Acid ReducerTablet, film coated150 mg/1OralRite Aid2011-10-26Not applicableUs
Acid ReducerTablet75 mgOralApotex Corporation1999-02-08Not applicableCanada
Acid ReducerTablet, film coated150 mg/1OralShopko Stores Operating2013-06-05Not applicableUs
Acid ReducerTablet150 mg/1OralFred's2012-03-30Not applicableUs
Acid ReducerTablet150 mg/1OralP & L Development Of New York Corporation2013-03-25Not applicableUs
Acid ReducerTablet150 mg/1OralH.E.B.2014-04-11Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DeramsilkRx Anodynexa PakRanitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)KitTopicalPatchwerx Labs2015-06-12Not applicableUs
DermacinRx Inflammatral PakRanitidine hydrochloride (150 mg/1) + Capsicum oleoresin (0.25 mg/1mL) + Diclofenac sodium (75 mg/1)KitTopicalPure Tek Corporation2015-06-12Not applicableUs
Inflammation Reduction PackRanitidine hydrochloride (150 mg/1) + Diclofenac sodium (75 mg/1) + Lidocaine (25 mg/1g) + Prilocaine (25 mg/1g)KitOralTmig, Inc.2015-08-18Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DeprizineRanitidine hydrochloride (6.4 g/6.4g)KitOralCalifornia Pharmaceuticals, Llc2016-01-012018-01-05Us
DeprizineRanitidine hydrochloride (4.2 g/4.2g)KitOralFusion Pharmaceuticals LLC2010-02-082014-08-01Us
GabitidineRanitidine hydrochloride (150 mg/1) + Choline (125 mg/1)KitOralPhysician Therapeutics Llc2011-07-07Not applicableUs
Ranitidine Hydrochloride Oral Suspension KitRanitidine hydrochloride (6.4 g/6.4g)KitOralCalifornia Pharmaceuticals, Llc2017-01-02Not applicableUs
SentradineRanitidine hydrochloride (150 mg/1) + Choline (250 mg/1)KitOralPhysician Therapeutics Llc2011-07-07Not applicableUs
International/Other Brands
Alquen / Gastrolav / Gastrosedol / Kuracid / Ptinolin / Raniberl / Ranicux / Ranidil / Ranidin / Ranidine / Ranidura / Ranigast / Raniplex / Ranisan / Ranitab / Ranitic / Ranitidin / Ranitin / Ranitine / Ranobel / Rantacid / Ranuber / Renatac / Sostril / Tanidina / Toriol / Ulcodin / Zandid / Zantic
Categories
UNII
884KT10YB7
CAS number
66357-35-5
Weight
Average: 314.4
Monoisotopic: 314.141261758
Chemical Formula
C13H22N4O3S
InChI Key
VMXUWOKSQNHOCA-UHFFFAOYSA-N
InChI
InChI=1S/C13H22N4O3S/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3/h4-5,9,14-15H,6-8,10H2,1-3H3
IUPAC Name
[1-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine
SMILES
CNC(NCCSCC1=CC=C(CN(C)C)O1)=C[N+]([O-])=O

Pharmacology

Indication

This drug is used alone or with concomitant antacids for the following conditions Label:

Duodenal ulcer

Treatment of active duodenal ulcer (short-term), maintenance therapy of duodenal ulcers after healing (reduced dose)

Pathological hypersecretion of gastric acid

Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions causing gastric acid hypersecretion

Gastric ulcer

Short term treatment of active gastric ulcer (benign), maintenance of healing after gastric acid ulcer therapy (reduced dose)

Other conditions:

Treatment of GERD symptoms (symptoms usually improve within 24 hours), treatment of erosive esophagitis (endoscopically diagnosed) and maintenance of healing Label

Associated Conditions
Pharmacodynamics

Ranitidine decreases the secretion of gastric acid stimulated by food and drugs. It also reduces the secretion of gastric acid in hypersecretory conditions such as Zollinger-Ellison syndrome 6, Label. Marked improvements in the appearance of the esophageal tissues have been observed by endoscopic imaging after ranitidine therapy 5.

Mechanism of action

After a meal, the hormone gastrin, produced by cells in the lining of the stomach, stimulates the release of histamine, which then binds to histamine H2 receptors, leading to the secretion of gastric acid. Ranitidine reduces the secretion of gastric acid by reversible binding to histamine (H2) receptors, which are found on gastric parietal cells. This process leads to the inhibition of histamine binding to this receptor, leading to the reduction of gastric acid secretion. The relief of gastric-acid related symptoms can occur as soon as 60 minutes after administration of a single dose, and the effects can last from 4-10 hours, providing fast and effective symptomatic relief 3,7.

TargetActionsOrganism
AHistamine H2 receptor
antagonist
Humans
UAcetylcholinesterase
inhibitor
Humans
UCholinesterase
inhibitor
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Ranitidine is 50% absorbed after an oral tablet and both the syrup and effervescent tablet formulations are found to be bioequivalent to the tablet form. After an intravenous (IV) injection, average peak levels of 440 to 545 ng/mL are attained about 2-3 hours after a single 150 mg dose. Food or antacids have limited effects on absorption. One clinical study found that the administration of a potent antacid (150 mmol) in subjects in the fasted state showed decreased absorption of ranitidine Label.

Volume of distribution

The volume of distribution is approximately 1.4 L/kg Label.

Protein binding

Approximately 15% Label.

Metabolism

The major metabolite in the urine is N-oxide, which represents less than 4% of the dose. Other metabolites of ranitidine include S-oxide (1%) and desmethyl ranitidine (1%). The feces contain the remainder of the excreted ranitidine dose. Liver dysfunction has been shown to cause small, but clinically insignificant, changes in various ranitidine pharmacokinetic parameters Label.

Route of elimination

This drug is mainly excreted in the urine. About 30% of a single oral dose has been measured in the urine as unchanged drug within 24 hours of ingestion Label.

Half life

2.5-3 hours Label. The plasma half-life is longer for elderly patients population due to a decrease in renal function, and is measured at 3-4 hours Label.

Clearance

Renal clearance is 78 about 410 mL/min Label. Clearance is decreased in the elderly and those with impaired renal function Label. It is recommended to decrease the dose of ranitidine by one-half in patients with renal impairment 10.

Toxicity

LD50

Oral doses of 1,000 mg/kg in mice and rats were not found to be lethal. Intravenous LD50 values in mice and rats were 77 and 83 mg/kg 9.

Overdosage

There has been limited experience with overdosage. Reported acute ingestions of up to 18 grams orally have been associated with temporary adverse effects that are similar to the normal adverse effects of this drug (see adverse effects section). Gait abnormalities and hypotension have also been observed. When overdose is suspected, attempt to remove unabsorbed ranitidine from the gastrointestinal tract, monitor the patient and provide supportive therapy as needed Label.

Pregnancy

Ranitidine is a pregnancy category B drug, meaning that animal studies have not shown harm caused by the drug to the fetus. Studies have been completed in rats and rabbits at doses reaching 160 times the human dose and have demonstrated that ranitidine does not exert effects on fertility or fetal growth. No sufficient and well-controlled studies in pregnant women have been performed. Because animal reproduction studies are not always reflective of human response, this drug should be used during pregnancy only if clearly required Label.

Nursing Mothers

Ranitidine has been detected in human breastmilk. Use caution ranitidine is given to a nursing mother Label.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ranitidine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Ranitidine.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Ranitidine.
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative and stimulatory activities of Ranitidine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ranitidine.
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Ranitidine.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Ranitidine.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Ranitidine.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Ranitidine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take without regard to meals.

References

Synthesis Reference

John W. Clitherow, "Intermediates in the preparation of ranitidine." U.S. Patent US4413135, issued November, 1981.

US4413135
General References
  1. Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F: Mania associated with ranitidine: a case report and review of literature. Fundam Clin Pharmacol. 2016 Aug;30(4):294-6. doi: 10.1111/fcp.12201. Epub 2016 May 5. [PubMed:27083385]
  2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. [PubMed:2667937]
  3. Pettit M: Treatment of gastroesophageal reflux disease. Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7. [PubMed:16341949]
  4. Badillo R, Francis D: Diagnosis and treatment of gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014 Aug 6;5(3):105-12. doi: 10.4292/wjgpt.v5.i3.105. [PubMed:25133039]
  5. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R: Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial. Arch Intern Med. 1987 Aug;147(8):1485-91. [PubMed:3307670]
  6. Vezzadini P, Bonora G, Tomassetti P, Pazzaglia M, Labo G: Medical treatment of Zollinger-Ellison syndrome with ranitidine. Int J Tissue React. 1983;5(4):339-43. [PubMed:6323334]
  7. Caitlin C. Nugent; Jamie M. Terrell (2018). H2 Blockers- StatPearls. StatPearls Publishing.
  8. FDA drug approval package: Zantac [Link]
  9. Zantac injection FDA label [File]
  10. Zantac Canadian Monograph [File]
External Links
Human Metabolome Database
HMDB0001930
KEGG Drug
D00422
PubChem Compound
3001055
PubChem Substance
46505543
ChemSpider
4863
BindingDB
50103506
ChEBI
92246
ChEMBL
CHEMBL1790041
Therapeutic Targets Database
DAP000340
PharmGKB
PA451224
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ranitidine
ATC Codes
A02BA07 — Ranitidine bismuth citrateA02BA02 — Ranitidine
AHFS Codes
  • 56:28.12 — Histamine H2-antagonists
FDA label
Download (1.03 MB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedBasic Science(t1/2,λz) / Cmax / Pharmacokinetics / Plasma [AUC(0-672)] / Plasma [AUC(0-t)] / Plasma AUC / Tmax1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceReflux Esophagitis (RE)1
1CompletedTreatmentHealthy Volunteers5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure / High Blood Pressure (Hypertension) / Pulmonary Arterial Hypertension (PAH)1
1SuspendedBasic ScienceDrug Interaction Potentiation / Inhibition Enzyme / Pharmacokinetics1
1TerminatedOtherHealthy Volunteers1
2CompletedDiagnosticGastro-esophageal Reflux Disease (GERD) / Reflux, Gastroesophageal1
2CompletedTreatmentCancer, Breast1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2RecruitingTreatmentPostpartum Haemorrhage (PPH)1
2TerminatedTreatmentHyper IgE Syndromes / Hyper-IgE Recurrent Infection Syndrome / Immune Deficiencies1
2TerminatedTreatmentT-cell Type Acute Leukemia-Precursor T-lymphoblastic Lymphoma/Leukaemia1
2, 3CompletedTreatmentHelicobacter Pylori [H. Pylori] as the Cause of Diseases1
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3CompletedTreatmentGastric Ulcer (GU)1
3CompletedTreatmentGastro-esophageal Reflux Disease (GERD)2
3CompletedTreatmentNSAID Associated Gastric Ulcers2
3CompletedTreatmentReflux, Gastroesophageal1
3RecruitingTreatmentDisseminated Sclerosis1
3TerminatedHealth Services ResearchCoughing1
3TerminatedTreatmentEsophageal Metaplasia1
4Active Not RecruitingBasic ScienceMalignancies1
4CompletedPreventionPulmonary Aspiration of Gastric Contents1
4CompletedTreatmentAntimicrobial Drug Susceptibility Pattern / Etiological Organisms / Stress Ulcer Prophylaxis / Ventilator-associated Bacterial Pneumonia1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentCoronary Artery Disease / Drug Interaction Potentiation / VA Drug Interactions [VA Drug Interaction]1
4CompletedTreatmentCritically Ill Patients / Indication for Stress Ulcer Prophylaxis1
4CompletedTreatmentIndigestion2
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
4Enrolling by InvitationTreatmentAnesthesia Complication / Hemodynamics Instability / Ileus paralytic / Nausea / Postoperative pain / Vomiting1
4RecruitingOtherCongenital Heart Disease (CHD) / Infection NOS / Stress Ulcers / Upper Gastrointestinal Hemorrhage1
4RecruitingPreventionProtamine Adverse Reaction1
4WithdrawnPreventionPeptic Ulcers1
4WithdrawnTreatmentEustachian Tube Dysfunction / Laryngopharyngeal Reflux1
Not AvailableCompletedNot AvailableCommunity Acquired Pneumonia (CAP) / Gastro-esophageal Reflux Disease (GERD)1
Not AvailableCompletedNot AvailablePharmacokinetics / Voriconazole1
Not AvailableCompletedNot AvailableStrokes1
Not AvailableCompletedSupportive CareAntiplatelet Effect1
Not AvailableCompletedTreatmentGastrointestinal Diseases / Indigestion1
Not AvailableCompletedTreatmentPost-Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedTreatmentPostoperative paralytic ileus1
Not AvailableUnknown StatusPreventionPoisoning1
Not AvailableWithdrawnTreatmentAcid Reflux / Laryngomalacia / Stridor1

Pharmacoeconomics

Manufacturers
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Glaxosmithkline
  • Bedford laboratories div ben venue laboratories inc
  • Ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Amneal pharmaceuticals
  • Apotex inc
  • Aurobindo pharma usa inc
  • Cypress pharmaceutical inc
  • Pharmaceutical assoc inc div beach products
  • Ranbaxy laboratories ltd
  • Vintage pharmaceuticals inc
  • Wockhardt ltd
  • Boehringer ingelheim pharmaceuticals inc
  • Amneal pharmaceuticals ny llc
  • Boehringer ingelheim corp
  • Contract pharmacal corp
  • Dr reddys laboratories inc
  • Glenmark generics inc usa
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • L perrigo co
  • Ranbaxy pharmaceuticals inc
  • Torpharm inc
  • Watson laboratories inc
  • Wockhardt americas inc
  • Boehringer ingelheim
Packagers
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • Aidarex Pharmacuticals LLC
  • Amerisource Health Services Corp.
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Apotheca Inc.
  • Apothecon
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Banner Pharmacaps Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Blenheim Pharmacal
  • Boehringer Ingelheim Ltd.
  • Bryant Ranch Prepack
  • Cardinal Health
  • Central Texas Community Health Centers
  • Chain Drug
  • Cobalt Pharmaceuticals Inc.
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Coupler Enterprises Inc.
  • CVS Pharmacy
  • Dept Health Central Pharmacy
  • DHHS Program Support Center Supply Service Center
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • DSM Corp.
  • Fusion Pharmaceuticals LLC
  • Genpharm LP
  • GlaxoSmithKline Inc.
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Innovative Manufacturing and Distribution Services Inc.
  • Innoviant Pharmacy Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Novopharm Ltd.
  • Nucare Pharmaceuticals Inc.
  • Ohm Laboratories Inc.
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patheon Inc.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Penn Labs
  • Perrigo Co.
  • Pharmaceutical Association
  • Pharmaceutical Packaging Center
  • Pharmedix
  • Physicians Total Care Inc.
  • Precision Dose Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescription Dispensing Service Inc.
  • Prx Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Roxane Labs
  • Sandhills Packaging Inc.
  • Sandoz
  • Shasun Chemicals & Drugs Ltd.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Sunmark
  • Teva Pharmaceutical Industries Ltd.
  • Torpharm Inc.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • Va Cmop Dallas
  • Vangard Labs Inc.
  • Vistapharm Inc.
  • Walgreen Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
  • Xactdose Inc.
Dosage forms
FormRouteStrength
TabletOral75 mg
TabletOral75.0 mg
KitOral4.2 g/4.2g
KitOral6.4 g/6.4g
KitTopical
TabletOral
InjectionIntramuscular; Intravenous25 mg/1mL
SolutionOral15 mg/1mL
SolutionOral15.0 mg/1mL
SolutionOral150 mg/1mL
SyrupOral15 mg/1mL
SyrupTopical15 mg/1mL
TabletOral150 mg
TabletOral300 mg
TabletOral75 mg/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral75 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral300 mg/1
CapsuleOral150 mg/1
CapsuleOral300 mg/1
PowderNot applicable1 g/1g
SolutionOral150 mg/10mL
SolutionOral75 mg/5mL
TabletOral150 mg/1
TabletOral300 mg/1
Tablet, film coatedOral75 mg/1
KitOral
SolutionIntramuscular; Intravenous
Injection, solutionIntramuscular; Intravenous25 mg/1mL
Injection, solutionIntravenous50 mg/50mL
LiquidIntramuscular; Intravenous25 mg
SolutionIntramuscular; Intravenous50 mg
SolutionOral15 mg
TabletOral84 mg/1
Tablet, effervescentOral25 mg/1
Tablet, effervescentOral150 mg/1
SolutionOral
CapsuleOral
Prices
Unit descriptionCostUnit
Zantac 300 mg tablet7.96USD tablet
Ranitidine hcl powder5.2USD g
Zantac EFFERdose 25 mg Effervescent Tabs4.18USD tab
Zantac 25 efferdose tablet4.02USD tablet
Zantac 150 mg tablet3.11USD tablet
Ranitidine HCl 300 mg capsule2.85USD capsule
Ranitidine HCl 300 mg tablet2.79USD tablet
Ranitidine 300 mg tablet2.69USD tablet
Ranitidine hcl 25 mg/ml vial2.0USD ml
Zantac 25 mg/ml vial2.0USD ml
Ranitidine HCl 150 mg capsule1.58USD capsule
Zantac 25 mg/ml1.58USD ml
Ranitidine HCl 150 mg tablet1.54USD tablet
Ranitidine 150 mg tablet1.48USD tablet
Ranitidine 25 mg/ml1.26USD ml
Ranitidine HCl 15 mg/ml Syrup1.0USD ml
Ratio-Ranitidine 300 mg Tablet0.82USD tablet
Apo-Ranitidine 300 mg Tablet0.82USD tablet
Co Ranitidine 300 mg Tablet0.82USD tablet
Mylan-Ranitidine 300 mg Tablet0.82USD tablet
Nu-Ranit 300 mg Tablet0.82USD tablet
Pms-Ranitidine 300 mg Tablet0.82USD tablet
Ran-Ranitidine 300 mg Tablet0.82USD tablet
Zantac 15 mg/ml Syrup0.81USD ml
Zantac 75 tablet0.49USD tablet
Apo-Ranitidine 150 mg Tablet0.42USD tablet
Co Ranitidine 150 mg Tablet0.42USD tablet
Mylan-Ranitidine 150 mg Tablet0.42USD tablet
Nu-Ranit 150 mg Tablet0.42USD tablet
Pms-Ranitidine 150 mg Tablet0.42USD tablet
Ran-Ranitidine 150 mg Tablet0.42USD tablet
Ratio-Ranitidine 150 mg Tablet0.42USD tablet
Novo-Ranidine 300 mg Tablet0.38USD tablet
Phl-Ranitidine 300 mg Tablet0.38USD tablet
Sandoz Ranitidine 300 mg Tablet0.38USD tablet
Zantac 300 mg Tablet0.38USD tablet
Zantac 75 mg tablet0.28USD tablet
Wal-zan 75 mg tablet0.27USD tablet
Zantac 15 mg/ml Solution0.23USD ml
Ranitidine hcl 75 mg tablet0.22USD tablet
Sm acid reducer 75 mg tablet0.22USD tablet
Acid reducer 150 mg tablet0.2USD tablet
Wal-zan 75 tablet0.2USD tablet
Novo-Ranidine 150 mg Tablet0.19USD tablet
Phl-Ranitidine 150 mg Tablet0.19USD tablet
Sandoz Ranitidine 150 mg Tablet0.19USD tablet
Zantac 150 mg Tablet0.19USD tablet
CVS Pharmacy ranitidine 75 mg tablet0.15USD tablet
Apo-Ranitidine 15 mg/ml Solution0.12USD ml
Novo-Ranidine 15 mg/ml Solution0.12USD ml
Acid reducer 75 mg tablet0.11USD tablet
CVS Pharmacy acid reducer 75 mg tablet0.11USD tablet
Qc ranitidine 75 mg tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5098715No1992-03-242010-12-20Us
US5102665No1992-04-072009-12-23Us
CA1332610No1994-10-182011-10-18Canada
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)134https://www.chemicalbook.com/ChemicalProductProperty_US_CB3685534.aspx
boiling point (°C)437.1±45.0http://www.chemspider.com/Chemical-Structure.571454.html
water solubilitysoluble in waterhttps://www.chemicalbook.com/ChemicalProductProperty_US_CB3685534.aspx
logP0.2https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf
Caco2 permeability0.49https://www.ncbi.nlm.nih.gov/pubmed/9755906
pKa 8.2 and 2.7https://www.fip.org/files/fip/BPS/BCS/Monographs/Ranitidine_Hydrochloride.pdf
Predicted Properties
PropertyValueSource
Water Solubility0.0795 mg/mLALOGPS
logP0.79ALOGPS
logP0.99ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)7.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.58 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity94.15 m3·mol-1ChemAxon
Polarizability33.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier-0.8783
Caco-2 permeable-0.5838
P-glycoprotein substrateSubstrate0.8527
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8893
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateSubstrate0.7414
CYP450 3A4 substrateNon-substrate0.5565
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7819
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8077
BiodegradationNot ready biodegradable0.9249
Rat acute toxicity2.0903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8628
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Targets

Details
1. Histamine H2 receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Pattichis K, Louca LL: Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview. Drug Metabol Drug Interact. 1995;12(1):1-36. [PubMed:7554999]
  2. Grant SM, Langtry HD, Brogden RN: Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Jun;37(6):801-70. doi: 10.2165/00003495-198937060-00003. [PubMed:2667937]
  3. Zantac FDA label [File]
Details
2. Acetylcholinesterase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036. [PubMed:15669026]
  2. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The inhibition of acetylcholinesterase by ranitidine: a study on the guinea pig ileum. J Pharmacobiodyn. 1986 Nov;9(11):941-5. [PubMed:3559884]
  3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563. [PubMed:2874096]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036. [PubMed:15669026]
  2. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The inhibition of acetylcholinesterase by ranitidine: a study on the guinea pig ileum. J Pharmacobiodyn. 1986 Nov;9(11):941-5. [PubMed:3559884]
  3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563. [PubMed:2874096]
  4. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [PubMed:8095733]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Curator comments
Data supporting this enzyme action are limited to in vitro studies.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3. [PubMed:10223772]
  2. Zhou Q, Yan XF, Zhang ZM, Pan WS, Zeng S: Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28. [PubMed:17948937]
  3. CYP1A2 table [File]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
Data regarding this enzyme action are limited to in vitro studies and show weak inhibition,
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3. [PubMed:10223772]
  2. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP: Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol. 2010 Jun 1;28(16):2768-76. doi: 10.1200/JCO.2009.23.8931. Epub 2010 May 3. [PubMed:20439629]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
Data limited to one in vitro study, with results showing weak inhibition and likely to have little clinical significance.
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Martinez C, Albet C, Agundez JA, Herrero E, Carrillo JA, Marquez M, Benitez J, Ortiz JA: Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76. doi: 10.1016/S0009-9236(99)70129-3. [PubMed:10223772]
  2. Ranitidine drug summary [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Petroianu GA, Arafat K, Schmitt A, Hasan MY: Weak inhibitors protect cholinesterases from strong inhibitors (paraoxon): in vitro effect of ranitidine. J Appl Toxicol. 2005 Jan-Feb;25(1):60-7. doi: 10.1002/jat.1036. [PubMed:15669026]
  2. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [PubMed:8095733]
  3. Aono M, Moriga M, Mizuta K, Narusawa H: Cholinergic effects of histamine-H2 receptor antagonists partly through inhibition of acetylcholinesterase. Gastroenterol Jpn. 1986 Jun;21(3):213-9. doi: 10.1007/bf02774563. [PubMed:2874096]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Meyer MJ, Seitz T, Brockmoller J, Tzvetkov MV: Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017. [PubMed:29236753]
  2. Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KL, Thakker DR: Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol. 2013 Aug;84(2):182-9. doi: 10.1124/mol.112.084517. Epub 2013 May 16. [PubMed:23680637]
Details
2. P-glycoprotein 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
  3. Collett A, Higgs NB, Sims E, Rowland M, Warhurst G: Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther. 1999 Jan;288(1):171-8. [PubMed:9862768]
  4. Dou L, Mai Y, Madla CM, Orlu M, Basit AW: P-glycoprotein expression in the gastrointestinal tract of male and female rats is influenced differently by food. Eur J Pharm Sci. 2018 Oct 15;123:569-575. doi: 10.1016/j.ejps.2018.08.014. Epub 2018 Aug 15. [PubMed:30118850]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Data for this transporter are limited to the results of an in vitro study.
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Meyer MJ, Seitz T, Brockmoller J, Tzvetkov MV: Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS One. 2017 Dec 13;12(12):e0189521. doi: 10.1371/journal.pone.0189521. eCollection 2017. [PubMed:29236753]
  2. Nies AT, Schwab M: Organic cation transporter pharmacogenomics and drug-drug interaction. Expert Rev Clin Pharmacol. 2010 Nov;3(6):707-11. doi: 10.1586/ecp.10.60. [PubMed:22111772]
  3. Straight Healthcare: OCT2 [Link]

Drug created on June 13, 2005 07:24 / Updated on October 16, 2019 13:15